Smart Nanoplatforms Responding to the Tumor Microenvironment for Precise Drug Delivery in Cancer Therapy

Wang, Yujie; Deng, Tingting; Liu, Xi; Fang, Xueyang; Mo, Yongpan; Xie, Ni; Nie, Guohui; Zhang, Bin; Fan, Xiaoqin

doi:10.2147/ijn.s459710

Cited by 3 publications

(1 citation statement)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These factors collectively enable the realization of stimuli-responsive TDDS, facilitating controlled drug release and enhanced drug accumulation at tumor sites, while concurrently reducing the toxic side effects on normal tissues. 138 , 139 …”

Section: Stimuli-responsive Targeted Drug Delivery Systemsmentioning

confidence: 99%

Advances on Delivery System of Active Ingredients of Dried Toad Skin and Toad Venom

Zhang,

Zhai,

Sun

et al. 2024

IJN

View full text Add to dashboard Cite

Dried toad skin (TS) and toad venom (TV) are the dried skin of the Bufo bufo gargarizans Cantor and the Bufo melanostictus Schneider , which remove the internal organs and the white secretions of the skin and retroauricular glands. Since 2005, cinobufacini preparations have been approved by the State Food and Drug Administration for use as adjuvant therapies in the treatment of various advanced cancers. Meanwhile, bufalenolides has been identified as the main component of TS/TV, exhibiting antitumor activity, inducing apoptosis of cancer cells and inhibiting cancer cell proliferation or metastasis through a variety of signaling pathways. However, clinical agents frequently face limitations such as inherent toxicity at high concentrations and insufficient tumor targeting. Additionally, the development and utilization of these active ingredients are hindered by poor water solubility, low bioavailability, and rapid clearance from the bloodstream. To address these challenges, the design of a targeted drug delivery system (TDDS) aims to enhance drug bioavailability, improve targeting within the body, increase drug efficacy, and reduce adverse reactions. This article reviews the TDDS for TS/TV, and their active components, including passive, active, and stimuli-responsive TDDS, to provide a reference for advancing their clinical development and use.

show abstract

Section: Stimuli-responsive Targeted Drug Delivery Systemsmentioning

confidence: 99%

Advances on Delivery System of Active Ingredients of Dried Toad Skin and Toad Venom

Zhang,

Zhai,

Sun

et al. 2024

IJN

View full text Add to dashboard Cite

show abstract

Advancements in drugs restructured with nanomedicines for multiple myeloma treatment

Liu,

Shen,

Liu

et al. 2024

Sci. China Mater.

View full text Add to dashboard Cite

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Rahman,

Ali

2024

Cancers

View full text Add to dashboard Cite

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years in the median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing the formation of new vasculature (antiangiogenic treatments) or destroying formed tumor vasculature (vascular disrupting agents) show promise. This study summarizes the existing knowledge regarding the processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses the activation of redundant proangiogenic pathways, heightened tumor cell invasion and metastasis, resistance induced by hypoxia, creation of vascular mimicry channels, and regulation of the tumor immune microenvironment. Subsequently, we explore potential strategies to overcome this resistance, such as combining antiangiogenic therapies with other treatment methods, personalizing treatments for each patient, focusing on new therapeutic targets, incorporating immunotherapy, and utilizing drug delivery systems based on nanoparticles. Additionally, we would like to discuss the limitations of existing methods and potential future directions to enhance the beneficial effects of antiangiogenic treatments for patients with GBM. Therefore, this review aims to enhance the research outcome for GBM and provide a more promising opportunity by thoroughly exploring the mechanisms of resistance and investigating novel therapeutic strategies.

show abstract

Smart Nanoplatforms Responding to the Tumor Microenvironment for Precise Drug Delivery in Cancer Therapy

Cited by 3 publications

References 131 publications

Advances on Delivery System of Active Ingredients of Dried Toad Skin and Toad Venom

Advances on Delivery System of Active Ingredients of Dried Toad Skin and Toad Venom

Advancements in drugs restructured with nanomedicines for multiple myeloma treatment

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Contact Info

Product

Resources

About